Table 3.
Condition | BDCIPP | DPHP | ip-PPP | |
---|---|---|---|---|
Implantation | ||||
Q1 | 0.71 (0.59, 0.81) | 0.72 (0.59, 0.81) | 0.69 (0.56, 0.79) | 0.74 (0.62, 0.83) |
Q2 | 0.62 (0.49, 0.73) | 0.58 (0.46, 0.70) | 0.64 (0.52, 0.75) | 0.50 (0.37, 0.62) |
Q3 | 0.57 (0.45, 0.69) | 0.53 (0.41, 0.65) | 0.56 (0.44, 0.68) | 0.61 (0.48, 0.72) |
Q4 | 0.49 (0.37, 0.62)* | 0.56 (0.43, 0.67) | 0.50 (0.38, 0.62)* | 0.54 (0.41, 0.66)* |
p-trend | 0.02 | 0.06 | 0.02 | 0.05 |
Pregnancy | ||||
Q1 | 0.63 (0.50, 0.74) | 0.61 (0.49, 0.73) | 0.61 (0.49, 0.72) | 0.63 (0.51, 0.74) |
Q2 | 0.54 (0.42, 0.66) | 0.50 (0.38, 0.62) | 0.55 (0.42, 0.66) | 0.40 (0.29, 0.53) |
Q3 | 0.50 (0.38, 0.62) | 0.47 (0.35, 0.59) | 0.48 (0.36, 0.60) | 0.51 (0.39, 0.63) |
Q4 | 0.37 (0.26, 0.50)* | 0.45 (0.33, 0.57) | 0.39 (0.28, 0.52)* | 0.48 (0.36, 0.61) |
p-trend | 0.004 | 0.06 | 0.01 | 0.19 |
Live birth | ||||
Q1 | 0.48 (0.35, 0.61) | 0.49 (0.36, 0.61) | 0.47 (0.34, 0.59) | 0.53 (0.40, 0.65) |
Q2 | 0.42 (0.30, 0.55) | 0.36 (0.24, 0.48) | 0.42 (0.30, 0.55) | 0.35 (0.24, 0.47) |
Q3 | 0.38 (0.27, 0.51) | 0.36 (0.25, 0.49) | 0.37 (0.26, 0.50) | 0.35 (0.24, 0.48) |
Q4 | 0.30 (0.20, 0.43)* | 0.36 (0.25, 0.49) | 0.31 (0.21, 0.44) | 0.35 (0.24, 0.48) |
p-trend | 0.05 | 0.20 | 0.07 | 0.05 |
Note: Adjusted models control for maternal age (continuous), body mass index (continuous), race/ethnicity (black/Asian/other, white/Caucasian), year of IVF treatment cycle (continuous), and primary Society for Assisted Reproductive Technology (SART) infertility diagnosis at study entry (female, male, unknown). Adjusted means are presented for the mean maternal age (35.2), body mass index (23.9), race/ethnicity (white), year of IVF treatment cycle (2010), and primary SART infertility diagnosis at study entry ( , ). BDCIPP, bis(1,3-dichloro-2-propyl) phosphate; DPHP, diphenyl phosphate; ip-PPP, isopropylphenyl phenyl phosphate; PFR, organophosphate flame retardant.
Significantly different from Q1 at the level.